Prezcobix is called Rezolsta in Europe.
Information about Prezcobix (Darunavir / Cobicistat)
Prezcobix is a combination medication containing darunavir, a protease inhibitor, and cobicistat, a pharmacokinetic enhancer. Darunavir works by inhibiting the action of the HIV-1 protease enzyme, which is necessary for the virus to replicate. Cobicistat, on the other hand, enhances the effectiveness of darunavir by inhibiting enzymes that metabolize it, allowing darunavir to remain active in the body for longer periods. Prezcobix is used in the treatment of HIV infection in combination with other antiretroviral agents.
Product Highlights
- Used as part of combination antiretroviral therapy (cART) to treat HIV-1 infection in adults and children over the age of 12.
- Prezcobix is often used as part of a treatment regimen to reduce the viral load of HIV in the bloodstream, improving the immune system's function and quality of life for HIV-positive individuals.
Key Ingredient
Key Benefits
- Prezcobix helps to lower the viral load of HIV-1, improving the immune system and reducing the risk of HIV transmission.
- The combination of darunavir and cobicistat allows for once-daily dosing, simplifying treatment adherence.
- Cobicistat boosts the effect of darunavir, ensuring that the protease inhibitor remains active in the body for an extended period, improving the effectiveness of the therapy.
- Prezcobix has a generally favorable side effect profile compared to other antiretroviral agents, making it a good option for long-term HIV management.
Direction of Use
- Prezcobix is taken once daily as a single tablet with food to improve absorption.
- The specific dosage depends on the individual’s treatment plan and the advice of their healthcare provider.
- It is crucial to take Prezcobix consistently as part of a comprehensive HIV treatment regimen and not to miss doses, as missing doses can lead to drug resistance.
- Regular follow-up appointments with a healthcare provider are essential to monitor treatment progress, manage side effects, and check for any signs of drug resistance.
Safety Concerns
- Prezcobix may cause liver problems, including hepatitis and elevated liver enzymes, especially in patients with a history of liver disease.
- Cobicistat can affect the metabolism of other drugs, so Prezcobix may interact with certain medications, including anticonvulsants, anticoagulants, and certain antibiotics.
- Allergic reactions to darunavir, such as skin rashes, can occur. Serious side effects may include Stevens-Johnson syndrome or toxic epidermal necrolysis, although they are rare.
- Prezcobix may increase the risk of heart-related side effects, particularly in patients with pre-existing heart conditions.
- Long-term use of Prezcobix can contribute to bone density loss, so monitoring bone health may be recommended for long-term users.
- Gastrointestinal side effects like nausea, diarrhea, and vomiting may occur, especially at the start of treatment.
Avoid Prezcobix (Darunavir / Cobicistat) If
- Do not take Prezcobix if you are allergic to darunavir, cobicistat, or any of the other ingredients in the medication.
- Avoid use if you have severe liver impairment or active liver disease, including cirrhosis or hepatitis.
- Prezcobix is not recommended during the first trimester of pregnancy, as cobicistat may affect the metabolism of other medications. Pregnant women should consult with their healthcare provider for alternative treatments.
- Avoid use with medications that strongly interact with cobicistat, such as certain anticonvulsants (e.g., carbamazepine, phenytoin), antiarrhythmics, or St. John’s Wort, unless advised by a healthcare provider.
- Prezcobix may not be suitable for patients with severe kidney impairment, as the combination of drugs may affect kidney function.
